603301 Zhende Medical
- 20.69
- 0.000.00%
Zhende Medical News
Express News | Zhende Medical: The company does not sell medical products such as masks in the US
Zhende Healthcare (603301): The revenue side can be expected to improve the quarter-on-quarter, and the regular business will accelerate growth
Results were under pressure in 2023 due to reduced demand for quarantine protective equipment and asset impairment. In 2023, the company achieved revenue of 4.127 billion yuan (-32.76%) and net profit to mother of 198 million yuan (-70.87%)
Investors Still Waiting For A Pull Back In Zhende Medical Co., Ltd. (SHSE:603301)
With a price-to-earnings (or "P/E") ratio of 43.5x Zhende Medical Co., Ltd. (SHSE:603301) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios
Zhende Medical (603301.SH) announced first-quarter results, net profit of 73.3976 million yuan, a year-on-year decrease of 49.89%
Zhende Medical (603301.SH) released its report for the first quarter of 2024. The company's revenue was 964 million yuan...
Zhende Medical (603301.SH): The ban on 39.2465 million restricted shares was lifted on March 26
Gelonghui March 20 丨 Zhende Medical (603301.SH) announced that the total number of shares in circulation in the company's current stock listing was 39.2465 million shares. The stock listing and circulation date is March 26, 2024.
Investors Could Be Concerned With Zhende Medical's (SHSE:603301) Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Amongst other things, we'll want to see two things; firstly, a growing return on
Zhende Medical (603301): Domestic and overseas two-wheel drive “medical+health” leads long-term development
The global medical dressing industry has spawned several large market capitalization companies, and the development of the domestic medical dressing industry has lagged behind overseas for decades. According to Grand View Research, the global wound dressing market reached 13.7 billion in 2022
Express News | Guoxin Securities gave Zhende Medical Buy an initial rating.
The medical device sector strengthened, and many other stocks such as Melander rose and stopped
Gelonghui, Feb. 8 | Mailand Biotech rose and stopped 20CM, Zhende Medical and Matilda Biotech went up and down, and Yingkang Life, Lanwei Medicine, and Maipu Medical surged more than 10%. According to news, in January 2024, the State Drug Administration approved the registration of a total of 321 medical device products. Among them, there are 247 domestic Class III medical device products, 41 imported Class III medical device products, and 33 Class II medical device products.
Is rapid contraction in performance+executives continuing to reduce their holdings by 2 billion dollars and expanding production as a burden, making Zhende Healthcare “difficult to revive again”?
① This evening, Zhende Medical released a performance forecast. Revenue and net profit for 2023 fell sharply, and the announcement of Zhende Medical's executive holdings reduction was also issued at the same time; ② The industry believes that Zhende Medical's performance and stock price trends are not surprising, and company executives may have chosen to reduce their holdings. Perhaps they feel that the company's stock price and performance may not improve significantly in the short term, and its ambitious production capacity construction and upgrade plans may need to be re-examined.
Some directors and supervisors of Zhende Medical (603301.SH) completed a total reduction of 65,800 shares
Zhende Medical (603301.SH) announcement, Xu Dasheng, director and deputy general manager of the company, Zhang Xiantao, chairman of the supervisory board...
Express News | Zhende Healthcare: Net profit is expected to decrease by 69.17% to 71.37% year-on-year in 2023
Zhende Medical Co., Ltd. (SHSE:603301) Has A ROE Of 11%
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business.
Zhende Medical (603301) 2023 Third Quarter Report Review: Short-term pressure on third-quarter results continues to enhance brand influence and market coverage
Matters: The company released its 2023 three-quarter report. In the first three quarters, the company's revenue was 3.209 billion yuan (-23.55%), net profit was 301 million yuan (-33.96%), net profit was 2.83 billion yuan (-33.96%), and non-net profit was 2.83.
Zhende Medical (603301): The impact of epidemic prevention products is gradually being clarified, and regular business growth is steady
Event: The company released its 2023 three-quarter report, 2023Q3 revenue of 900 million yuan (-36.9%), net profit of 0.6 billion yuan (-65.6%). Total revenue for the first three quarters of 2023 was 3.21 billion yuan (-23
Zhende Healthcare (603301.SH) released the first three quarter results, net profit of 301 million yuan, a year-on-year decrease of 33.96%
Zhende Medical (603301.SH) released its report for the third quarter of 2023. The company achieved operating income of 3 in the first three quarters...
Zhende Medical (603301.SH) plans to pay 7.5 yuan for every 10 shares for the half-year, excluding interest on October 31
Zhende Medical (603301.SH) announced that the company plans to distribute every 10 shares to all shareholders for the semi-annual period of 2023.
Some Investors May Be Worried About Zhende Medical's (SHSE:603301) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a perfect world, we'd like to see a company investing more capital into its business and
Zhende Medical and Yunnan Baiyao Taibang reached a strategic cooperation
Gelonghui September 24 | Zhende Medical announced that it has officially launched a strategic cooperation with Yunnan Baiyao Taibang to jointly open a new chapter of pharmaceutical cooperation with many domestic pharmacy chains. The two sides use protective gear as the basis for cooperation. In the future, they will carry out more in-depth cooperation in more fields to provide consumers with better and more product choices.
Declining Stock and Decent Financials: Is The Market Wrong About Zhende Medical Co., Ltd. (SHSE:603301)?
Zhende Medical (SHSE:603301) has had a rough three months with its share price down 14%. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with fut
Analysis
Price Target
No Data
